Molecular You, a Vancouver-based healthtech startup, has raised $6.9 million CAD ($5M USD) in Series A funding to accelerate the rollout of its predictive blood testing platform across North America.
The round was led by Voloridge Health, with participation from Dynamic Leap and other undisclosed investors.
Founded in 2014, Molecular You provides a direct-to-consumer health platform that analyzes more than 250 biomarkers from a single blood draw, offering users a snapshot of whole-body health, early risk detection for diseases like Alzheimer’s and liver disease, and personalized lifestyle recommendations.
The fresh capital will fuel customer growth, clinical partnerships, and the introduction of a next-generation test capable of measuring over 800 biomarkers — expanding into areas such as cancer detection.
“This investment allows us to scale access to predictive testing and advance towards higher-resolution analysis that can transform preventative care,” said Jim Kean, CEO of Molecular You.
Advertisement
Expanding footprint and clinical validation
The company launched nationwide in the US this year via a partnership with HealthQuest Esoterics, enabling insurance reimbursement. Its platform has already delivered impactful results, including detecting early signs of pancreatic cancer in a customer’s biomarker data, as detailed in a peer-reviewed OMICS journal report.
With the wellness industry valued at $6.3 trillion globally, Molecular You joins Canadian peers like NiaHealth and Fullscript, while differentiating itself with a platform that blends biomarker testing, AI-driven insights, and insurance-supported distribution.
